The 2025 South Central AUA annual meeting included a session on bladder cancer, featuring a presentation from Dr. Yair Lotan ...

The immune checkpoint inhibitor combination regimen has become the initial standard of care for metastatic RCC, given its ...

Table 1. Metric comparison between robotic and laparoscopic donor nephrectomy approaches.

In a real-world, multi-center cohort, patients receiving LHRH agonists as compared to LHRH antagonists were found to be at ...

Moderated by Dr. Thomas Chi (UAB), the panel featured Dr. Vernon Pais (Dartmouth), Dr. Karen Stern (Mayo Clinic Arizona), Dr.

Neoadjuvant systemic therapy was acceptable to 70% of patients, with 69% of those willing to undergo renal mass biopsy first. While 52% would consider neoadjuvant systemic therapy for ≥16 weeks and 56 ...

Neoadjuvant Therapy for Men with High Risk Disease Prior to Prostatectomy - Mary-Ellen Taplin ...

These results suggest that anti-CTLA4 ICI synergizes with the Ad-PS2 vaccine to generate a robust cytotoxic T-cell response capable of inducing both primary tumor clearance and long-term resistance, ...

WCET 2025: Suction Technology Utility in Mini-PCNL Study: Results of a Real World Multicenter Registry on Behalf of the Endourology Section of the European Association of Urology and the Suction Mini ...

Dr. Valdes concluded this presentation discussing whether artificial intelligence can match multidisciplinary expertise in managing high and very high risk prostate cancer with positive surgical ...

Detalimogene voraplasmid is a novel, investigational, non-integrating, non-viral genetic medicine-based immunotherapy carrying a plasmid that simultaneously expresses IL-12 and regulators of RIG-I.

On the other hand, radium-223 dichloride is an alpha particle-emitting calcium mimetic that selectively targets bone metastases and induces double-stranded DNA breaks. In the ALSYMPCA trial, ...